TLX · Telix Pharmaceuticals Limited American Depositary Shares
View on chartInsiders & Stakes
| Behrenbruch Christian MD & Group CEO | ▲ Buy | Open Market | 20,742,935 Shares held | 4/29/2026 | View profile |
| Smith Darren Charlton Group Chief Financial Officer | ▲ Buy | Open Market | 13,992 Shares held | 9/7/2026 | View profile |
Transaction History
| Smith Darren Charlton | ▲ Buy | Open Market | 2,071 | $20K | 9/7/2026 |
| Behrenbruch Christian | ▲ Buy | Open Market | 33,435 | $497K | 4/29/2026 |
| Behrenbruch Christian | ▲ Buy | Open Market | 34,500 | $500K | 4/28/2026 |
| Smith Darren Charlton | ▲ Buy | Option Exercise | 1,111 | $0 | 3/29/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Telix doses first US patients with FDA-approved Pixclara
Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.
Telix doses first US patients with FDA-approved Pixclara. Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.